Ligand Pharmaceuticals, Inc. (LGND)
316.05
-2.73
(-0.86%)
USD |
NASDAQ |
Oct 29, 15:15
Ligand Pharmaceuticals Enterprise Value : 6.124B for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 6.124B |
| October 27, 2026 | 5.983B |
| October 26, 2026 | 5.915B |
| October 23, 2026 | 5.820B |
| October 22, 2026 | 5.905B |
| October 21, 2026 | 6.044B |
| October 20, 2026 | 5.877B |
| October 19, 2026 | 5.696B |
| October 16, 2026 | 5.661B |
| October 15, 2026 | 5.720B |
| October 14, 2026 | 5.650B |
| October 13, 2026 | 5.820B |
| October 12, 2026 | 5.971B |
| October 09, 2026 | 5.786B |
| October 08, 2026 | 5.650B |
| October 07, 2026 | 5.615B |
| October 06, 2026 | 5.689B |
| October 05, 2026 | 5.885B |
| October 02, 2026 | 5.809B |
| October 01, 2026 | 5.804B |
| September 30, 2026 | 5.996B |
| September 29, 2026 | 5.956B |
| September 28, 2026 | 6.031B |
| September 25, 2026 | 5.780B |
| September 24, 2026 | 5.731B |
| Date | Value |
|---|---|
| September 23, 2026 | 5.718B |
| September 22, 2026 | 5.720B |
| September 21, 2026 | 5.552B |
| September 18, 2026 | 5.421B |
| September 17, 2026 | 5.445B |
| September 16, 2026 | 5.256B |
| September 15, 2026 | 5.291B |
| September 14, 2026 | 5.364B |
| September 11, 2026 | 5.440B |
| September 10, 2026 | 5.536B |
| September 09, 2026 | 5.512B |
| September 08, 2026 | 5.527B |
| September 04, 2026 | 5.463B |
| September 03, 2026 | 5.545B |
| September 02, 2026 | 5.489B |
| September 01, 2026 | 5.436B |
| August 31, 2026 | 5.433B |
| August 28, 2026 | 5.361B |
| August 27, 2026 | 5.441B |
| August 26, 2026 | 5.508B |
| August 25, 2026 | 5.386B |
| August 24, 2026 | 5.355B |
| August 21, 2026 | 5.477B |
| August 20, 2026 | 5.499B |
| August 19, 2026 | 5.565B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 679.85B |
| Eli Lilly & Co. | 1.259T |
| Merck & Co., Inc. | 394.68B |
| ANI Pharmaceuticals, Inc. | 1.882B |
| Corcept Therapeutics, Inc. | 9.013B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 48.51M |
| Revenue (Quarterly) | 63.69M |
| Total Expenses (Quarterly) | 15.18M |
| EPS Diluted (Quarterly) | 2.221 |
| Gross Profit Margin (Quarterly) | 82.24% |
| Profit Margin (Quarterly) | 76.16% |
| Earnings Yield | 2.96% |
| Operating Earnings Yield | 1.52% |
| Normalized Earnings Yield | 2.227 |